---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-25-000063"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:01:47.736511+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio Q2 net loss narrows to $38.6M; rosnilimab Phase 2b RA data positive

## Summary
- Net loss $38.6M ($1.34/sh) vs $46.7M ($1.71) YoY; collaboration revenue $22.3M, up from $11.0M.
- Cash & investments $293.7M as of June 30, 2025; cash runway through year-end 2027 reiterated.
- Rosnilimab RA Phase 2b shows JAK-like efficacy, durable off-drug response; UC Phase 2 enrollment complete, top-line Q4 2025.
- ANB033 (CD122 antagonist) to begin Phase 1b in celiac disease by Q4 2025; R&D event planned.
- Anticipate $75M GSK milestone in 2025 once Jemperli achieves $1B annual net sales.

## SEC filing metadata
- accession: 0001370053-25-000063
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005325000063/0001370053-25-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005325000063/anab-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-25-000063
- JSON: https://secwatch.observer/filing/0001370053-25-000063.json
- Plain text: https://secwatch.observer/filing/0001370053-25-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.